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eGF receptor (eGFR) inhibition 
promotes a slow-twitch oxidative, 
over a fast-twitch, muscle 
phenotype
Margherita Ciano1, Giada Mantellato2, Martin Connolly2, Mark paul-Clark2, Saffron Willis-owen2,  
Miriam F. Moffatt  2, William o. C. M. Cookson  2, Jane A. Mitchell2, Michael I. polkey3, 
simon M. Hughes  4, paul R. Kemp2 & s. Amanda Natanek2
A low quadriceps slow-twitch (ST), oxidative (relative to fast-twitch) fiber proportion is prevalent in 
chronic diseases such Chronic obstructive pulmonary Disease (CopD) and is associated with exercise 
limitation and poor outcomes. Benefits of an increased ST fiber proportion are demonstrated in 
genetically modified animals. Pathway analysis of published data of differentially expressed genes in 
mouse ST and FT fibers, mining of our microarray data and a qPCR analysis of quadriceps specimens 
from COPD patients and controls were performed. ST markers were quantified in C2C12 myotubes with 
EGF-neutralizing antibody, EGFR inhibitor or an EGFR-silencing RNA added. A zebrafish egfra mutant 
was generated by genome editing and ST fibers counted. EGF signaling was (negatively) associated 
with the st muscle phenotype in mice and humans, and muscle EGF transcript levels were raised in 
COPD. In C2C12 myotubes, EGFR inhibition/silencing increased ST, including mitochondrial, markers. In 
zebrafish, egfra depletion increased ST fibers and mitochondrial content. EGF is negatively associated 
with st muscle phenotype in mice, healthy humans and CopD patients. eGFR blockade promotes 
the ST phenotype in myotubes and zebrafish embryos. EGF signaling suppresses the ST phenotype, 
therefore EGFR inhibitors may be potential treatments for COPD-related muscle ST fiber loss.
Conditions such as Chronic Obstructive Pulmonary Disease (COPD), cardiac failure, type 2 diabetes, obesity 
and muscle wasting are major healthcare issues in ageing populations1. In these conditions, exercise capacity, 
whole-body metabolism and glucose homeostasis are impaired and since they are highly dependent on skeletal 
muscle, the proportion of slow-twitch (ST) to fast-twitch (FT) fibers in the large locomotor muscles has signifi-
cant clinical impact2. This is because, in man, ST, type I, fibers are energy-efficient, mitochondria-rich, adapted for 
fat and glucose oxidation, and more insulin-sensitive3, resistant to fatigue4 and chronic disease-related wasting5,6 
than FT oxidative/glycolytic IIa and glycolytic IIx fibers. A reduced quadriceps ST fiber proportion is prevalent 
in COPD (affecting more than half of patients with moderate to very severe lung disease)5,7,8, as well as in cardiac 
failure6, type 2 diabetes and obesity9,10. Quadriceps ST fiber proportion is an independent predictor of reduced 
maximal exercise capacity5 and also mortality11 in COPD. It is also an independent predictor of reduced maximal 
exercise capacity in patients with cardiac failure and type 2 diabetes12,13 and of insulin resistance9 and adiposity10. 
In COPD, the increased population of hybrid ST/IIa fibers in the quadriceps muscle indicate that ST fibers are 
switching to FT8. An opposite FT to ST switch can be induced in animal models with manipulation of neuromus-
cular stimulation patterns and forced transcription factor and co-activator expression14,15 but not with exercise 
in patients16. Drugs targeting relevant pathways to increase ST fibers in skeletal muscle would therefore be novel 
therapies for exercise limitation in COPD and metabolic disease2,17, and would be anticipated to reduce these 
patients’ susceptibility to muscle atrophy because of ST fibers relative resistance to atrophy.
Here we report that inhibition of an EGFR-driven pathway promotes the ST muscle phenotype in vitro and in 
vivo, and demonstrate that this pathway appears relevant to COPD-related ST fiber loss in the locomotor muscles.
1Department of Medicine, imperial college London, London, UK. 2national Heart and Lung institute, imperial 
college London, London, UK. 3Royal Brompton and Harefield NHS Foundation Trust, London, UK. 4Randall Division 
of cell & Molecular Biophysics, King’s college London, London, UK. correspondence and requests for materials 
should be addressed to S.A.n. (email: a.natanek@imperial.ac.uk)
Received: 30 August 2018
Accepted: 10 April 2019
Published: xx xx xxxx
opeN
2Scientific RepoRts |          (2019) 9:9218  | https://doi.org/10.1038/s41598-019-45567-4
www.nature.com/scientificreportswww.nature.com/scientificreports/
Results
Muscle eGF transcripts are negatively associated with a st phenotype in mice. Pathway analysis 
of differentially expressed genes in isolated mouse ST and FT IIb fibers data-mined from18 identified EGF sign-
aling as the top signaling pathway negatively associated with ST phenotype, together with EGF receptor (ErbB) 
and mitogen-activated protein kinase/extracellular signal-related kinase (ERK) signaling, the latter a key pathway 
activated by EGFR in response to EGF19 and previously implicated in muscle fiber-type regulation20,21 (Fig. 1a and 
Supplementary Fig. E1). This led us to investigate EGF and EGFR expression in muscle from healthy humans and 
COPD patients.
Muscle EGF transcript levels correlate negatively with ST fiber proportion in COPD patients and 
healthy controls. We have previously published a genome-wide expression analysis of quadriceps biopsies 
from 79 COPD patients and 16 healthy matched controls from this cohort followed by a Weighted Correlation 
Network Analysis (WGCNA) of the results22. This analysis revealed six modules of co-expressed transcripts, of 
which two (labelled ‘yellow’ and ‘turquoise’) showed the strongest correlation with type I fiber proportion and 
maximal aerobic exercise capacity. By conducting an exhaustive screening of all possible glm models predicting 
type I fiber proportion and maximal aerobic exercise capacity from the six previously defined co-expression mod-
ules, we show here that the yellow module yields the greatest overall support, and relative to the other modules, 
represents the most important term in predicting exercise capacity (Supplementary Fig. E2A and E2B).
Within the yellow module documented in22, EGF has the second highest absolute module membership 
(MM 0.81); a measure of eigengene-based connectivity widely applied for the identification of intramodular 
hub genes. Also showing high levels of module membership is SOX6 (MM 0.77) encoding the sex determining 
region y-related Box 6, a transcription factor shown elsewhere to suppress ST fiber development in mice23 and 
zebrafish24.
Figure 1. Pathway analysis of mouse data and human muscle analysis. (a) Pathways overlapping with genes 
downregulated in mouse ST versus FT IIb fibers identified through the use of IPA (QIAGEN Inc., https://www.
qiagenbioinformatics.com/products/ingenuitypathway-analysis)48. Z-scores <0 (blue bars) and = 0 (white 
bars) signify more, or equal, pathway activations compared to inhibitions respectively reported in association 
with downregulated genes, grey indicating absence of directionality data. See methods for ratio; threshold 
indicates statistical significance. (b,c) Human muscle microarray data (participant characteristics in Table 1). 
(b) Quadriceps EGF transcripts in controls, COPD low and normal ST: patients with a ST fiber proportion 
<27% and ≥27% respectively. Mean (SD) and t-test results shown. (c) Quadriceps EGF transcripts versus ST 
fiber proportions (r = −0.69, p = 0.003 in controls, r = −0.56 in patients and −0.62 in patients with controls, 
both p <z0.0001). (d,e) QPCR data for small COPD cohort (Table 1). (d) Quadriceps EGF transcripts in low 
and normal ST groups. Median (IQR) and Mann-Whitney U-test results shown. E: Quadriceps EGF transcripts 
versus ST fiber proportions (r = −0.56, p = 0.019). *as for Table 1.
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To explore these findings further we extracted EGF transcript levels from25 and assessed the relationship 
between its abundance, disease status and ST fiber proportion. COPD patients had higher EGF transcript levels 
in the quadriceps, with the highest levels in patients with a low ST fiber proportion (both p < 0.0001, Fig. 1b, 
normal ST proportion >27% according to reference ranges from7). Quadriceps EGF transcript abundance and 
ST fiber proportion were negatively correlated in patients (r = −0.56, p < 0.0001), controls (r = −0.69, p = 0.003), 
and in both groups when combined (r = −0.62, p < 0.0001, Fig. 1c). EGF mRNA levels were also negatively cor-
related with maximal aerobic exercise capacity measured as peak oxygen consumption on an incremental cycle 
test (Supplementary Fig. E2C). Array data was replicated by qPCR using RNA from separate residual quadriceps 
specimens from COPD patients with ST fiber proportions that were very low (median 13%, range 2–24%, n = 8) 
or within normal range (median 39%, range 30–48%, n = 9); 12 patients were in the microarray study, 5 were 
additional (Table 1). EGF transcript abundance was again highest in patients with a low ST fiber proportion 
(p = 0.036, Fig. 1d), and negatively correlated with ST fiber proportion (r = −0.56, p = 0.019, Fig. 1e) and muscle 
endurance (r = −0.64, p = 0.01, Supplementary Fig. E3A) in patients. Serum EGF protein levels did not differ-
entiate patients and controls, nor patients based on ST fiber proportions (Supplementary Fig. E3D). Quadriceps 
EGFR mRNA levels were not different between patient groups, nor correlated with ST fiber proportion or EGF 
mRNA levels (Supplementary Fig. E3B,C). Together the data suggest that muscle EGF signaling as a result of EGF 
derived within muscle influences ST fiber proportion in humans and that increased EGF signaling in the quadri-
ceps muscle of COPD patients may underlie ST fiber loss. We therefore investigated effects of inhibiting skeletal 
muscle EGF signaling in vitro.
EGFR inhibition in differentiated muscle cells increases ST gene expression. EGF signaling 
blockade was investigated in C2C12 mouse myotubes using 3 approaches (i) pharmacological EGFR inhibition 
with AG-1478 (a selective, reversible inhibitor of the tyrosine kinase domain) (ii) EGFR knock-down using an 
siRNA and (iii) an EGF neutralizing antibody. Three days of AG-1478 increased transcripts of ST fiber-specific 
contractile components such as myosin heavy chain I (MyHC I, MYH7) and slow troponin I (TNNT1), and 
decreased FT fiber-specific transcripts, such as MYH2, 1 and 4 that respectively encode MyHC IIa, IIx and IIb 
(latter absent in man) (Fig. 2a). Increased MyHC I protein was confirmed with immunohistochemistry (Fig. 2d 
and Supplementary Fig. E4). AG-1478 also increased transcripts associated with mitochondrial oxidative metab-
olism such as citrate synthase (CS), mitochondrial uncoupling protein 3 (UCP3). Consistent with this observa-
tion, AG-1478 treatment increased MitoTracker Red staining of functional mitochondria in myotubes indicating 
an overall increase in mitochondrial activity (Fig. 2d and Supplementary Fig. E5). AG-1478 also increased tran-
scripts of insulin-responsive glucose transporter 4 (GLUT4/SLC2A4), which is more highly expressed in ST mus-
cle26 (Fig. 2a). 1 hour after AG-1478 treatment there was a very modest reduction in phosphorylated EGFR 
(pEGFR)/total EGFR but this was associated with reductions in downstream pERK/ERK (1 and 2) and pAkt/
Akt compared to treatment with vehicle control, each time the experiment was run (n = 3, representative image 
in Fig. 2e and additional images and quantification in Supplementary Fig. E6A). Similar results were observed 
24 hours after the final treatment (i.e. 24 hours after the third daily treatment) with AG-1478 compared to treat-
ment with vehicle control, and also at 1 hour after treatment with AG-1478 plus 100 ng/ml EGF compared to 
treatment with vehicle control plus 100 ng/ml EGF (the additional EGF used to enhance the baseline signal) 
(Supplementary Fig. E6B,C).
Knocking down EGFR with a silencing RNA increased transcripts encoding MyHC I, TNNT1, and CS, UCP3 
and GLUT4, and increased MyHC I protein and staining of functional mitochondria (Figs 2b,d, Supplementary 
Figs E7 and E8), compared to control-transfected cells. There were additional smaller increases in transcripts 
encoding FT MyHC IIa and IIb (Fig. 2b) not seen with AG-1478. The siRNA knocked down EGFR protein and 
reduced pERK/ERK and pAkt/Akt, each time the experiment was run (n = 3, representative image in Fig. 2e and 
Microarray cohort PCR cohort
Patients 
(n = 79)
Controls 
(n = 16)
COPD low 
ST (n = 32)
COPD 
normal ST 
(n = 47)
COPD 
low ST 
(n = 9)
COPD 
normal ST 
(n = 8)
Age (years) 67 (8) 66 (7) 66 (6) 68 (9) 61 (14) 75 (11)*
Sex (% males) 65 50 62 69 66 100
FEV1 (% predicted) 45 (18) 109 (14)**** 38 (14) 50 (20) 21 (6) 48 (50)***
TLCO (% predicted) 43 (17) 90 (16)**** 35 (17) 48 (16) 27 (17) 54 (18)****
Quadriceps endurance (T80, s) 80 (35) 118 (139)* 75 (30) 85 (34) 83 (64) 90 (35)
Peak VO2 (ml/kg/min) 12.3 (4.0) 23.4 (7.6)**** 11.6 (4.8) 12.7 (3.4)* 8.8 (3.0) 10.7 (4.5)
% ST fibers 30 (18) 54 (22)*** 18 (14) 36 (11)**** 13 (20) 39 (8)***
% I/IIa fibers 3 (5) 2 (6)* 3 (6) 3 (5) 2 (9) 2 (6)
% FT IIa fibers 60 (12) 40 (13)**** 69 (12) 56 (12)**** 69 (11) 59 (13)*
% FT IIx fibers 4 (9) 3 (6) 8 (13) 2 (6)*** 8 (13) 2 (6)
Table 1. COPD patient and healthy control characteristics in cohort used for microarray and PCR. Mean 
(SD) or median (IQR) shown, t-test, Mann Whitney U-test, and Fisher’s exact test as appropriate, *p < 0.05, 
**p < 0.01, ***p < 0.005, ****p < 0.0001. FEV1 Forced Expiratory Volume in 1 second, TLCO carbon 
monoxide diffusion capacity, T80 time for force to drop to 80% of initial, VO2 oxygen consumption on maximal 
incremental cycle ergometry.
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additional images and quantification in Supplementary Fig. E6A). Together with the AG-1478 data, this demon-
strated that both pharmacological and genetic EGFR inhibition promoted the ST muscle phenotype in vitro.
Next, we reduced the concentrations of EGF in the cell culture medium (present as a result of the addition of 
horse serum27 and any secretion from cells). Addition of EGF neutralizing antibody (EGFnAb) to the medium 
increased transcripts encoding MyHC I but decreased all other mRNAs measured (Fig. 2c). Addition of the 
antibody did not reduce pERK1/ERK or pERK2/ERK2 but did cause a modest reduction in pEGFR/EGFR and 
pAkt/Akt 1 hour after treatment, each time the experiment was run (n = 3, representative image in Fig. 2e and 
additional images and quantification in Supplementary Fig. E6A). 24 hours after the final treatment (i.e. 24 hours 
after the third daily treatment) 24 hours after the final treatment (the third day of treatment) there was a mod-
est reduction in pEGFR/EGFR but no reduction in markers of downstream signaling (Supplementary Fig. E6B 
and E6C). Therefore EGF depletion from medium decreased EGFR phosphorylation status but did not suppress 
downstream ERK signaling as EGFR blockade had, nor did it increase ST gene expression. This may relate to the 
presence of alternative EGFR ligands, which are known to have different downstream signaling patterns28, in the 
medium that maintain suppression of the ST muscle phenotype despite reduction in EGF concentrations.
egfra depletion increases ST fiber development and mitochondrial content in zebrafish. After demonstrating that 
EGFR inhibition promotes the ST phenotype in vitro, we investigated EGFR signaling in vivo. We confirmed that 
egfra is widely expressed in larvae 2 dpf29 using mRNA in-situ hybridization (Supplementary Fig. E9), then gener-
ated an early nonsense mutation in egfra (egfrakg134) in zebrafish embryos with CRISPR/Cas9 (see Supplementary 
Figs E10 and E11 and Supplementary Information for details). Homozygous egfrakg134 zebrafish larvae died 
early, consistent with Egfr-knockout lethality in mice30. At 2 dpf, heterozygous egfra+/kg134 larvae expressed 
approximately 50% less egfra transcript (Fig. 3a), and had a significantly greater (16 ± 2%) number of ST fib-
ers per somite, without somite size differing, compared to wild-type (WT) siblings (Fig. 3b–e, Supplementary 
Video E12). Consistent with this, transcripts of sox6, a suppressor of ST fiber development in zebrafish24 were 
(50%) lower (Fig. 3a), while mitochondrial DNA content was 50% greater, in heterozygotes than WT siblings 
(Fig. 3f). egfra depletion therefore promotes the ST muscle phenotype in this in vivo model.
Figure 2. EGF pathway inhibition in myotubes. (a–d) QPCR data from mouse myotubes treated with AG-1478 
(a), EGFR siRNA (b), EGF neutralizing antibody (EGFnAb) (c), PD98059 (d), or respective vehicle controls. 
(e) MitoTracker Red and MyHC I staining intensity of myotubes treated as in (a,b). Mean(SEM) shown, n = 12/
group for qPCR, n = 8/group for staining (2 experiments, 2–6 different biological replicates per experiment, 2 
technical replicates per sample, t-test or Mann-Whitney U-test used depending on data distribution). * as for 
Table 1. Representative images of Western Blot bands from samples treated with (a) and (c) or vehicle control 
(Co control, Tr treated) and lysed 1-hour post-single dose, and 3 days following siRNA or control vector 
transfection. Phosphorylated and total protein quantifications are from the same membrane.
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Discussion
Our results, from human muscle and varying in vitro and in vivo experiments using pharmacological and 
genetic approaches, suggest that increased EGF-EGFR signaling contributes to ST fiber loss in COPD patients 
and demonstrate that EGFR signaling blockade promotes the development and maintenance of the ST muscle 
phenotype. EGF, and ErbB receptor, signaling was first identified from pathway analysis of mouse data before a 
consistent negative association between quadriceps EGF transcripts and ST fiber proportions was demonstrated 
in healthy elderly humans and in COPD patients, and EGF expression was found to be higher in patients than 
controls, and higher in patients with an abnormally low ST fiber proportion compared to patients with a ST fiber 
proportion within normal range. Consistent with EGF signaling being a regulator of fiber type, EGFR blockade in 
differentiated mouse muscle cells in culture increased ST (including mitochondrial) gene and protein expression, 
effects not recapitulated by reducing EGF levels in the medium. Furthermore, in an in vivo model using another 
vertebrate species, the zebrafish, and in the context of development, we found a similar role of EGFR signaling 
blockade again: egfra depletion resulted in an increased number of ST fibers. The data suggest that the EGF-EGFR 
signaling mechanism is an important pathway in regulating skeletal muscle fiber type which has been conserved 
across species. Moreover, it raises the possibility that EGFR blockade will have some therapeutic value in COPD 
patients with a low quadriceps ST fiber proportion, where this is associated with exercise limitation and mortality 
and may also predispose patients to muscle wasting as FT fibers are more prone to COPD-related atrophy than 
ST fibers5,31. EGFR inhibitors, such as gefitinib and erlotinib, are in the clinic as cancer treatments. Since our data 
suggests that modest EGFR blockade modifies muscle phenotype, lower, and hence more tolerable, doses than 
those used in cancer treatment regimens (which aim for total downstream signaling blockade32,33) may be effica-
cious in COPD patients. Further data supporting this hypothesis could be gained from investigating muscle ST 
fiber proportion in patients receiving EGFR inhibitor treatment for cancer.
The data is novel because no previous data implicates EGFR activation in skeletal muscle fiber-type specifica-
tion nor identifies a signaling mechanism related to ST fiber loss in COPD that is targetable by clinically available 
pharmacotherapies. Our results are, however, in keeping with the finding that Scube2 proteins, which contain 
EGF-like repeats, are pivotal for ST fiber development in zebrafish34, and previous literature implicating ERK1/2 
signaling (which is activated by EGFR signaling19) in fiber-type specification. Consistent with our results, Shi et al. 
have reported greater activity of ERK in mouse FT, compared to ST, muscles35, and that ERK inhibition increases 
slow myosin expression in vitro and in non-regenerating mouse and rat FT muscles20. However, ERK1/2 activa-
tion (rather than inhibition) has been implicated in re-establishing the slow muscle programming in rat soleus 
muscle (but not fast muscle) following denervation-induced ST to FT switch21. This suggests the context and 
Figure 3. egfra depletion on ST fiber development and mitochondrial content. Analysis of 2 dpf egfr+/kg134 
larvae and WT siblings. (a) QPCR data (n = 4 (pool of 5 larvae)/group, from 2 outcrosses). Smyhc1 and 
mylz2 encode slow MyHC and fast myosin light chain respectively. (b) Maximum intensity projections of 
immunostained ST fibers (scale bar = 50 µm). (c–e) ST fiber number (C), length (D) and lateral surface area (E) 
of somites 16–18. n = 16/group (5–6 larvae, 3 crosses, Mann-Whitney U-test). (f) Mitochondrial DNA content 
n = 12/group, from 2 outcrosses. Mean (SEM) and t-test results shown. *as for Table 1.
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presence of additional regulators dictates fiber-type effects in response to ERK signaling, and is consistent with 
the fact that ERK signaling is activated by a number of upstream pathways, not only EGFR signaling. For exam-
ple, insulin growth factor 1 signaling activates ERK in skeletal muscle36 but has not previously been described to 
induce fiber-type specific gene expression37. Our data suggest a reduction in pAkt in response to EGFR inhibition, 
raising the possibility that treatment with an EGFR inhibitor would reduce muscle protein synthesis and thereby 
muscle mass. How likely such an outcome would be, in a clinical context, is open to conjecture, as is any impact 
on physiology. Multiple regulators signal via Akt in vivo each with their own subset of outcomes. Inhibiting one 
of these regulatory pathways (in this case the EGFR pathway) may have minimal effect on overall Akt activity 
but a specific impact on the outcomes related to that pathway. As IGF-1 appears to be the major regulator of Akt 
in muscle influencing protein synthesis, EGFR may not have a significant impact on muscle mass. Furthermore, 
the positive effect on oxidative phenotype may outweigh any reductions in muscle mass on clinically relevant 
endpoints like exercise performance on submaximal exercise tests remains to be seen.
The cell culture differences resulting from varied disruption of EGF signaling warrant discussion. AG-1478 
treatment suppressed expression of FT IIb myosin transcripts unlike the EGFR siRNA, suggesting that this may 
have resulted from effects of AG-1478 on ErbB2-4 receptors or off-target effects. The relevance to humans, given 
that they do not express MyHC IIb is debatable. EGFnAb in the medium decreased expression of ST and mito-
chondrial markers, apart from ST myosin, in contrast to EGFR blockade. An inadequate decrease in EGF con-
centrations from the medium is one possible explanation of the findings. If the main EGF source for the muscle 
was not accessible to the EGFnAb, which could occur if cell-derived EGF was retained in the matrix, is one possi-
ble explanation. This suggestion is consistent with sequestration of muscle-derived EGF within the extracellular 
matrix during regeneration without circulating EGF rising38 and with our human data correlating muscle, but not 
circulating, EGF with ST fiber proportions. Alternatively, or additionally, the EGFnAb experiment results could 
reflect non-EGF mediated EGFR (and other ErbB receptor) activation, released by the removal of competition of 
these ligands with EGF. Since signaling downstream of EGFR is specific to the particular ligand28,39 it would not 
be surprising that the phenotype produced differs to that expected with reduced EGF-induced EGFR activation. 
In any case, this experiment suggests that the effects of EGFR blockade and systemically administered EGF neu-
tralizing antibody on skeletal muscle phenotype differ.
Limitations. The study focused on the role of EGF signaling in fiber-type specification, and the therapeutic 
potential of inhibiting it, hence the focus on loss-of-function experiments. The focus was on describing the clin-
ical phenotype of increased ST gene expression/fibers with EGFR inhibition, rather than describing mechanistic 
aspects such as which of the known signaling mechanisms downstream of EGFR responsible for the pheno-
type change, as this is not relevant to translation to clinical studies of EGFR inhibitors. However, we appreciate 
that these mechanistic studies and also gain-of-function studies would be interesting and produce more indepth 
insights. Cell culture has limitations in modelling what happens in vivo, regardless of cell type. We used C2C12 
myotubes rather than primary cells from humans because this was simpler, associations between EGF and fiber 
type were the same in mouse and human, and C2C12 myotubes beyond 6 days of differentiation express more 
FT than ST myosin40 resembling the pattern in patients. We used AG-1478 rather than an EGFR inhibitor in the 
clinic, because the likely required dose ranges were well-outlined and the mechanism of action of AG-1478 and 
the commercial inhibitors are identical41. We appreciate that there were differences in the experimental design 
of the EGFR inhibitor and siRNA cell culture experiments, necessitated by the difficulty of introducing genetic 
material into fully differentiated myotubes, but were reassured by the similarities between findings despite this. 
The zebrafish was a practical model to address our question because of ease of breeding and tracking ST fib-
ers which lateralize within the somite early in development42. Had we performed the experiment in mice, this 
would have necessitated generating a muscle-specific inducible knockout of EGFR. This is because of the pre- and 
post-natal lethality of early EGFR knockout and also the ubiquitous role of EGFR in many tissues, such that that 
knockout in non-muscle tissues may have significant secondary effects on muscle. The use of a zebrafish rather 
than a mammalian model, and a developmental/myogenesis model rather than an adult in vivo model, could be 
viewed as limitations. However, the observation that inhibition of EGF signaling promotes the ST phenotype in 
this different context reassured us of the consistent role of EGF in ST fiber specification. It could also be argued 
that there is a more direct relevance of our developmental/myogenesis data. Fast-to-slow fiber type transitions 
in adult animals, at least when induced by changes in electrical stimulation, have been shown to involve recruit-
ment of satellite cells, such that ablation of satellite cells by irradiation attenuates the fiber type transitions43,44. In 
quadriceps of COPD patients there is evidence of increased satellite cell recruitment to regenerating muscle fibers 
than in controls, in the form of increased numbers of fibers with centralised nuclei45–47. Therefore, if EGFR inhi-
bition promotes commitment of satellite cells to a ST muscle phenotype this would promote FT to ST fiber-type 
switching in adult muscle. We didn’t replicate the work in a mammalian model as the data already gathered 
appears to be sufficient to proceed to the next step -a prospective observational study of muscle fiber type changes 
in cancer patients treated with EGFR inhibitors.
In conclusion, we describe that EGFR inhibition promotes the ST muscle phenotype, a mechanism that 
appears conserved across species and scenarios of both myogenesis and fiber maintenance, and that increased 
EGF signaling is associated with a loss of the ST phenotype in COPD patients as well as being negatively associ-
ated with the ST muscle phenotype in mice. These findings suggest that studies of muscle fiber type in patients 
receiving EGFR inhibitor treatment for cancer would be valuable to determine whether EGFR inhibitors have this 
effect in humans in vivo, and therefore whether EGFR inhibitors may have therapeutic potential for patients, for 
example with COPD, with a locomotor muscle ST to FT fiber-type.
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Methods
pathway analysis. Data relating to differentially expressed genes in isolated mouse ST and FT IIb fibers 
taken from18 were analyzed through the use of IPA (QIAGEN Inc., https://www.qiagenbioinformatics.com/
products/ingenuitypathway-analysis)48 to identify ST phenotype-associated pathways (see Supplementary 
Information).
CopD patient and healthy control study. Vastus lateralis samples were collected for the study in5 which 
details clinical phenotyping, biopsy technique, and fiber typing. Studies were approved by the Royal Brompton 
and Harefield NHS Foundation Trust and Ealing and West London Mental Health Trust Research Ethics 
Committees (Studies 06/Q0404/35 and 06/Q0410/54) and all participants gave informed consent. Samples were 
stored in accordance with the Human Tissue Authority guidelines. The microarray analysis is described in25 and 
RNA extraction, cDNA synthesis and real-time quantitative PCR and quantification of serum EGF concentra-
tions by ELISA are detailed in the Supplementary Information.
Cell culture experiments. C2C12 mouse myoblasts49 were differentiated for 7 days into multinucleate 
myotubes, which co-express ST and FT myosins within single cells. From day 8 myotubes were treated daily 
for 3 days with 100 ng/ml EGF neutralizing antibody (EGFnAb) or 200 nM tyrphostin/AG-1478 or the respec-
tive vehicle control. 200 nM AG-1478 reportedly elicits preferential EGFR inhibition (IC50 of 3 nM compared to 
>100 uM for ErbB2 and PDGF receptors50 in vitro) and downstream MAPK/extracellular related kinase (ERK) 
signaling inhibition in different cells51,52. Myoblasts were also transfected with 1.5 μM siRNA to EGFR or scram-
bled negative control, differentiated for 3 days then lysed for RNA or stained with anti-MyHC I antibody (DSHB 
Cat# BA-F8, RRID: AB_10572253) or MitoTracker Red (ThermoFisher Scientific). qPCR was performed with 
HPRT as the housekeeping gene. (This approach was used because transfection efficiency of genetic material into 
fully differentiated myotubes is poor without electroporation53). Protein was extracted from myotubes treated 
as above and from myotubes treated with same AG-1478 and EGFnAb concentrations and lysed 1-hour post 
dose. Extracts were immunoblotted for phosphorylated EGFR (phosphorylated at tyrosine 1068, 175 kDa), and 
for markers of downstream EGFR signaling, pERK [pERK1 phosphorylated at Thr202 and/or Tyr204 (44 kDa), 
pERK2 phosphorylated at Thr185 and/or Tyr187 (42 kDa)] and pAkt (Akt 1, 2 and 3 phosphorylated at serine 
473, 60 kDA), then stripped and re-probed for total proteins (for the 1-hour post dose samples). Details are in the 
Supplementary Information.
Zebrafish experiments. Zebrafish on the AB background were housed and manipulated under UK Home 
Office Licence and standard procedures54. Whole-mount in situ hybridization for egfra was performed to confirm 
egfra expression as previously55. The CRISPR/Cas9 system was used to generate exon 1 egfra gene mutations 
and F3 generation allele number kg134 heterozygotes and their WT siblings were analysed (see Supplementary 
Information for details). RNA and DNA were extracted from pools of 5 larvae at 2 days post-fertilisation (dpf) 
for qPCR (normalization to geomean of beta-2 microglobulin and TATA-binding protein transcripts) and 
from single larva for genotyping. F2 egfra+/kg134 males were crossed to tagged ß-actin: GFP Tg(Ola.Actb:Hsa.
HRAS-EGFP)vu119 line56 females. Resulting GFP-positive egfra+/kg134 larvae and WT siblings were immunostained 
with anti-myosin antibody (DSHB Cat# A4.1025, RRID: AB_528356) at 2 dpf and ST fibers which exist at the 
outer somite border were counted in a standard somite sample (16–18) by an investigator blind to genotype.
statistical analysis. Exhaustive glm model comparison was carried out using the model selection and mul-
timodel inference package glmulti, applying the Akaike information criterion. Continuous data was compared 
with a two-tailed t-test or Mann Whitney U-test depending on normality. Categorical data and correlations 
were analysed using Fisher’s exact test and calculation of Pearson’s coefficient respectively. A p-value < 0.05 was 
deemed statistically significant.
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